cyrilzakka/clinical-trials huggingface dataset:
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.

This study seeks to define the role of gallium nitrate in a specific population of patients who are expected to have received prior therapy. Preliminary clinical studies have suggested substantial evidence of antitumor activity in patients with relapsed or refractory non-Hodgkin's Lymphoma treated with gallium nitrate.

Eligibility Criteria:
Low- or intermediate-grade NHL using the International Working Formulation, subtypes IWF A-G:

Using the Updated REAL/WHO Classification, the following pathologic subtypes are eligible:

* Small lymphocytic lymphoma
* Lymphoplasmacytic lymphoma/immunocytoma
* Follicular lymphoma
* Diffuse large B-cell lymphoma
* Peripheral T-cell lymphoma, not otherwise characterized

Progression of disease following treatment with standard chemotherapy

Bi-dimensionally measurable disease

Performance Status: ECOG \< = 2

Patients with mantle cell lymphoma or mycosis fungoides are not eligible

Patients with known history of CNS metastasis are not eligible
Physical Virtual Training for Older Women

The purpose of this study will be assess the effectiveness of the physical virtual training on nonspecific chronic low back pain, body balance, functional autonomy and mood of older women. Two groups will be formed. One will do strength exercises and core training. The other group will do the same exercises more virtual activities with Nintendo Wii. Will be measure pre and post-intervention of the responses already shown above.


Eligibility Criteria:
Inclusion Criteria:

* subjects with nonspecific chronic low back pain
* patients without involvement in regular exercise program

Exclusion Criteria:

* patients not recommended for physical exercise (Physical Activity Readiness Questionnaire PAR-Q)
* trunk surgery
* cancer
* injuries in lower extremity
* neurological or vestibular disease
Testing the Effect of ENDS Flavors on Neurotransmission

The overarching goal of this translational proposal is to determine if neuroactive flavor chemicals can enhance the addiction potential of electronic nicotine delivery systems (ENDS) by altering brain function and behavior.

For this randomized double-blind controlled trial, tobacco users will be randomized to use ENDS with an e-liquid containing a neuroactive flavor (hexyl acetate) vs. an inactive flavor (ethyl acetate) for ten days as a supplement to their typical tobacco use. Laboratory measures of ENDS reinforcement, subjective ENDS ratings, and brain reactivity to the flavor using functional magnetic resonance imaging (fMRI) will be collected at baseline and after ten days of ENDS use.

Eligibility Criteria:
Inclusion Criteria:

1. 21 to 60 years old
2. Regular users of inhaled tobacco products (≥5 days out of the last 28)
3. Not planning to quit tobacco use within next month
4. Able to read and write in English

Exclusion Criteria:

1. Major neurological conditions or brain trauma
2. Current substance use impairing participation
3. Unstable or significant medical conditions (e.g., COPD, coronary heart disease)
4. Current use of smoking cessation medication (e.g., varenicline, patch)
5. Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months
6. Known allergic reaction to ENDS liquids ingredients propylene glycol or vegetable glycerin
7. Unable to use study provided ENDS ad-libitum for at least 3 hours per day
8. Pregnant or breastfeeding as indicated by self-report or urine pregnancy screen

MRI-specific exclusion criteria:

1. MRI safety contraindications (e.g., metal implants, claustrophobia)
2. Major neurological conditions or brain trauma
Food Safety, Security and Waste Prevention Intervention on the KAB-P Approach of University Students

The goal of this clinical trial is aimed to examine the effect of food safety and security and waste reduction education on the knowledge, attitudes, behavior, and practices of undergraduates.

The main questions it aims to answer are:

Will the food consumption record of the experimental group be lower than the control group after the training? Will the experimental group's post-training food insecurity scale scores be higher than the control group? Will the experimental group's waste level be lower after the training than the control group? Will the experimental group's food safety knowledge test scores be higher than the control group?

Initiatives aimed at ensuring access to safe, nutritious, and adequate food and the reduction of food waste are critical for social well-being and sustainable development. This project is aimed to examine the effect of food safety and security and waste reduction education on the knowledge, attitudes, behavior, and practices of undergraduates. The research was designed as a randomized controlled trial in which the pre-test-post-test method will be applied. The participants of the study will consist of 110 (n intervention = 55, n control = 55) students studying at Selcuk University with the G\*Power 3.1.9.7 power analysis program. A grading randomization method will be used accordingly to the faculties. Through the research, participants will be provided with training consisting of 14 sessions on food safety, food security, and the reduction of food waste. Research data will be collected with; general information part, 24-hour recalled food consumption record, Food Insecurity Experience Scale, food consumption frequency form, management of food consumption-related behaviors, and food waste questionnaire form, and Food Safety, Attitudes, and Behaviors Scale. In addition, body weight (kg), height (m), waist (cm), hip (cm), and neck (cm) measurements will be taken from the participants in the study. The research findings will be analyzed by t-test in the groups dependent on the changes within the intervention and control groups; t-test in the independent groups. Furthermore, the Cohen d power level will be calculated, and the group time interaction between the groups will be evaluated by two-way analysis of variance and partial ETA recalculation in repetitive measurements. In case of data loss, a Little's Mcar test will be performed based upon the result of which the data will be analyzed and evaluated via the Intention-to-treat protocol by completing the data.

Eligibility Criteria:
Inclusion Criteria:University students who

* are not diagnosed with any chronic disease,
* do not use drugs constantly,
* do not follow a special diet,
* have not received any training on food safety-security and waste, and volunteer to participate in the study will be included in the study.

Exclusion Criteria:

* diagnosed with chronic disease,
* use drug constantly,
* follow a special diet,
* received any training on food safety-security and waste
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed


Eligibility Criteria:
Inclusion Criteria:

* Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including those requiring neo-adjuvant or adjuvant androgen deprivation therapy in association with radiotherapy
* Patients having provided written informed consent
* Patients mentally fit for completing a self-administrated questionnaire

Exclusion Criteria:

* Patients participating in another clinical study at the time of inclusion
* Patients with another severe malignant disease
* Life expectancy of less than 12 months
* Patients already treated with a LHRH analogue within the last year
Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia

The primary objective of this research is to measure changes in neurochemical concentrations during stimulation of the primary visual cortex, in both conditions of normoxia (normal oxygen availability) and induced mild hypoxia (reduced oxygen availability).

The goal is to determine the effect of mild hypoxia on human brain energy metabolism of healthy young adult subjects. For this purpose, the Investigator will utilize non-invasive imaging modalities based on functional magnetic resonance spectroscopy (fMRS) to estimate metabolic changes during a visual stimulus, while subjects are exposed to well-controlled gas mixtures that resembles conditions of either normoxia or mild hypoxia. Identifying the impact of mild hypoxia on functional brain energy metabolism in the healthy human brain is a crucial step for generating hypotheses in multiple patient populations that experience mild hypoxia as consequence of their pathological condition, such as in sleep apnea and traumatic brain injury. The Investigator hypothesize that the energetic demands of neuronal activation as revealed by fMRS will not be affected by mild hypoxia.

Eligibility Criteria:
Inclusion Criteria:

* Those volunteers who are evaluated as normal and not met exclusion criteria will be potential candidates for this study.

Exclusion Criteria:

* Subjects with any type of bio-implant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.).
* Subjects with any type of ferromagnetic bio-implant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc.
* Females.
* Subjects that exhibit noticeable anxiety and/or claustrophobia.
* Subjects who cannot adhere to the experimental protocol for any reason.
* Subjects who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function).
* Subjects who have known conditions which can lead to emergency medical care.
* Been diagnosed by a physician as having a psychiatric disorder, substance abuse, neurological, cardiovascular.
* Been diagnosed by a physician as having respiratory diseases.
* Had a brain tumor or stroke.
* Started taking chemotherapy or immunomodulatory agents, or had any radiation treatment that could affect the brain.
* Had two or more seizures, or been given a diagnosis of epilepsy.
* Gotten a non-removable piercing or permanent eyeliner.
* Had a head injury that caused you to lose consciousness for more than 30 minutes or have amnesia for more than 24 hours.
* Anyone with a history of sleep apnea or head trauma that may have caused Traumatic Brain Injury (TBI).
* Gotten some type of metal in your body, either from a medical procedure or an injury.
* Male subjects with long beard which wouldn't allow a complete seal between the mask and the face.
* Anyone who is not able to see long distance without glasses or contacts.
Use of Airtime Structure to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

This study evaluates the effect of three different airtime incentive structures on interactive voice response (IVR) survey cooperation, response, refusal and contact rates, as compared to a control group, in Bangladesh and Uganda.

Using random digit dialing (RDD) sampling technologies, participants were randomized to one of three airtime incentive structures contingent on them completing the noncommunicable disease risk factor survey. This mobile phone survey was sent as an interactive voice response (IVR). In IVR surveys, participants use their touch tone key pad to answer pre-recorded questions. (i.e. if you are male, press 1; if you are female, press 2). This study is being conducted in both Bangladesh and Uganda.

Eligibility Criteria:
Inclusion Criteria:

* Access to a mobile phone
* Greater or equal to 18 years of age
* In Bangladesh, conversant in either English or Bangla language. In Uganda, conversant in either Luo, Runyakitara, Luganda or English languages.

Exclusion Criteria:

* Less than 18 years of age
Effect of Early Mobilization on Regional Lung Ventilation Assessed by EIT

Changes in pulmonary ventilation and perfusion by EIT to out-of-bed activity in critically ill patients

1. EIT measurements were performed in ICU patients who under out-of-bed activity
2. Measurement of EIT was taken place at 4 time points: supine position before early mobilization, 30min, 60min during early mobilization, supine positon after early mobilization. All of them were without invasive ventilation. Measurements were made in triplicate at all time points.

Eligibility Criteria:
Inclusion Criteria:

* adult patients was performed out-of-bed activity in the ICU department based on doctor order
* Age (\> 18 years old) and (\< 90 years old)

Exclusion Criteria:

* Chest skin is injury and cannot be monitored by EIT
* The patients or their families refused to participate in the study
Histopathologic Effect of Calcium Electroporation on Cancer in the Skin

In this phase II study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.

In this non randomized phase II study, we will explore histopathological tumour cell death mechanisms in 24 patients with breast cancer metastases or other cutaneous or subcutaneous malignancy. The primary endpoint of the biopsy study is to evaluate differences in tumour infiltrating lymphocyte (TIL) population in tissue samples from treated cancer tumours two days after calcium electroporation treatment compared to samples taken on the day of treatment before the calcium electroporation procedure. TIL content in biopsies will be evaluated by pathological examination and specified in percent of cells. Patients will be followed up to 3 months and depending on number of treated tumors, biopsies will be taken at different timepoints after one or two treatments with calcium electroporation. Other analyses will include differences regarding tumour type, immune marker expression levels over time, vascular effects and regressive changes as well as examining changes in systemic immunological markers.

Eligibility Criteria:
Inclusion Criteria:

* Trial subject must be able to understand the participant information.
* Histologically verified cutaneous or subcutaneous, primary or secondary cancer of any histology.
* The patient can undergo any simultaneous medical treatment (endocrine therapy, chemotherapy, immunotherapy etc.).
* The patient can undergo radiation therapy during the study period, provided that the treatment field does not involve the treated area.
* Performance status ECOG/WHO ≤2
* At least one cutaneous or subcutaneous tumour measuring at least 5 mm.
* Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.)
* Signed informed consent.

Exclusion Criteria:

* Pregnancy or lactation
* Allergy to local anaesthesia
LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA

The aim of this study is to describe the results of Lateral Pharyngoplasty in the treatment of snore and OSAS.


Eligibility Criteria:
Inclusion Criteria:

* snore
* osas

Exclusion Criteria:

* previous pharynx surgery
* use of medication that modifies the muscular tonus or the perception of sleepiness before or after the surgery
* body mass index (BMI) bigger than 35 kg/m2
* neurological or psychiatric disease.
Effect of Different Methodologies on Variability of Brachial Artery Flow Mediated Dilation

Flow mediated dilation (FMD) of the brachial artery has been widely used as a non-invasive measure of endothelial function. FMD independently predicts future cardiovascular events and can be readily influenced by pharmacological, dietary or lifestyle interventions. However, the interpretation of FMD data is currently importantly hampered by differences in measurement methodologies and analysis techniques between laboratories. These differences result in large variation of 'normal' values between laboratories, highlighting the need for adopting widely supported and evidence-based guidelines.

Background: Flow mediated dilation (FMD) of the brachial artery has been widely used as a non-invasive measure of endothelial function. FMD independently predicts future cardiovascular events and can be readily influenced by pharmacological, dietary or lifestyle interventions.

Need for a review: Differences in methodology, guidelines (to control for moderating factors) and analysis techniques contribute to large variation in FMD between laboratories, limiting the widespread use and interpretation of FMD data.

Objectives: To identify methodological and technological factors that contributes to the variability (i.e. repeatability) of the brachial artery FMD. This will allow for development of quality guidelines for FMD measurement based on systematic data analysis.

Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Data sources: MEDLINE, EMBASE Chemical Abstracts, Biosis and The Cochrane Central Register of Controlled Trials will be searched using appropriate search terms.

Study selection: Observational cohorts and control groups of intervention studies with ≥ 50 subjects.

Methods: A list of quality criteria for scoring of FMD data will be defined both by expert consensus and by thorough review of the literature. Subsequently, a database of brachial artery FMD data (from published data and available individual data) will be compiled. The investigators will investigate which of the quality criteria significantly contribute to the variability of FMD by multiple meta-regression analyses. This data set will also allow us to investigate which quality criteria have the strongest impact on the variability of the FMD, to further refine the list of quality criteria.

Eligibility Criteria:
Inclusion Criteria:

* Observational cohorts and control groups of intervention studies with ≥ 50 subjects

Exclusion Criteria:

* ≤ 50 subjects
* Any co-intervention in control groups of intervention studies
Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation

Ventricular Tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. The concern is if adjunctive continuation amiodarone after ablation is needed.

Ischemic cardiomyopathy patients have implantable cardioverter defibrillators (ICD) to prevent arrhythmic deaths. Ventricular tachycardia (VT) events with frequent ICD interventions in ischemic cardiomyopathy patients is encountered frequently. Frequents ICD interventions is associated with worse outcomes. Anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and ICD interventions that may not be curative. Ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. After ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated.

In this study we aimed to enroll ischemic cardiomyopathy patients having frequent ICD interventions despite medical treatment. VT ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. Both groups will be compared in terms of recurrence and death.

Eligibility Criteria:
Inclusion Criteria:

Ischemic cardiomyopathy patients applied with frequent ICD interventionor electrical storms and having ejection fraction below 50%. Frequent ICD defined as more than 1 ICD intervention within month. Electrical storm defined as more than 2 ICD intervention within one day.

Exclusion Criteria:

Patients with cardiomyopathies other than ischemic etiology
Turkish Isolated Coronary Ectasia Registry: The T-ICE Registry

The T-ICE study is a prospective, observational study aiming to have information about the treatment and long-term prognosis of patients with isolated coronary artery ectasia.

Coronary artery ectasia is a localized or diffuse enlargement of the coronary artery lumen ≥1.5-2 times relative to the normal segment. It is often associated with coronary artery stenosis. Some patients have coronary artery ectasia without stenosis. This condition is called as isolated coronary artery ectasia. There is data other than retrospective studies with a small number of cases on the clinical significance, prognosis and treatment of isolated coronary ectasia in patients with or without acute coronary syndrome. Therefore, the treatment of patients with isolated coronary ectasia is not evidence-based and is based on the clinical judgment of physicians. The aim of this prospective observational study is to evaluate the treatment and prognosis of the isolated coronary artery ectasia. The second aim is to compare the prognosis of isolated coronary ectasia with the coronary artery disease.

Eligibility Criteria:
Inclusion Criteria:

* Isolated coronary artery ectasia (without ≥20% stenosis in any coronary artery ≥2 mm in diameter).
* All patients with isolated coronary ectasia with or without acute coronary syndrome will be included.
* Patients aged ≥18 years.
* Patients with discrete coronary artery aneurysm will be included.

Exclusion Criteria:

* Life expectancy \<24 months
* Patients with ≥20% stenosis in a vessel ≥2 mm in diameter.
Intra-articular Injection in Arthroscopic Management of Temporomandibular Diseases

The aim of this study is to evaluate the efficacy of intra-articular injection of platelet rich plasma versus hyaluronic acid following diagnostic arthroscopy in the management of patients suffering from degenerative temporomandibular joint (TMJ).

This is a prospective randomized study of 20 patients with TMJ degenerative joint diseases Wilkes IV, V.

Patients will be divided into two groups; Group A: will be treated with operative arthroscopy plus intra-articular platelet rich plasma.

Group B: will be treated with operative arthroscopy plus intra-articular hyaluronic acid.


Eligibility Criteria:
Inclusion Criteria:

* - All patients with reduced mouth opening and/or painful maximum mouth opening.
* Joint pain.
* Patients with radiological evidence of degenerative joint disease.
* Patients with unsuccessful medical conservative treatment for at least two months.
* Unilateral or bilateral temporomandibular joint involvement.
* Wilkes stages IV and V

Exclusion Criteria:

* - Patients with bony ankylosis .
* Patients with advanced resorption of the glenoid fossa.
* Patients with infection or tumors around joint area
* Patients unfit for intervention medically.
* Patients who refused to share in the study